Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
DexCom
DXCM
5
Collegium Pharmaceutical
COLL
US Stock MarketDetailed Quotes
SONN Sonnet BioTherapeutic
- 1.3400
- +0.0300+2.29%
Close Mar 31 16:00 ET
4.11MMarket Cap-0.13P/E (TTM)
1.3500High1.2200Low33.03KVolume1.2700Open1.3100Pre Close42.09KTurnover1.10%Turnover RatioLossP/E (Static)3.07MShares16.800052wk High1.02P/B4.03MFloat Cap1.220052wk Low--Dividend TTM3.01MShs Float329609.2800Historical High--Div YieldTTM9.92%Amplitude1.2200Historical Low1.2740Avg Price1Lot Size
About Sonnet BioTherapeutic Company
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.
Company Profile
SymbolSONN
Company NameSonnet BioTherapeutic
Listing DateJun 21, 2012
Founded2011
CEODr. Pankaj Mohan, PhD
MarketNASDAQ
Employees13
Fiscal Year Ends09-30
Address100 Overlook Center,Suite 102
CityPrinceton
ProvinceNew Jersey
CountryUnited States of America
Zip Code08540
Phone1-609-375-2227
Websitehttp://www.sonnetbio.com
Company Executives
- Name
- Position
- Salary
- Dr. Pankaj Mohan, PhD
- Chairman of the Board, President and Chief Executive Officer
- 1.02M
- Susan Dexter
- Chief Technical Officer
- --
- John H. Cross
- Chief Financial Officer and Principal Accounting Officer
- 619.25K
- Dr. Richard Kenney, M.D.
- Chief Medical Officer
- --
- Dr. John K. Cini, PhD
- Chief Scientific Officer
- 626.41K
- Donald J. Griffith, C.P.A.
- Director and Controller
- 137.33K
- Lori McNeill
- Independent Director
- 73.85K
- Raghu Rao
- Independent Director
- 120.35K
- Nailesh Bhatt
- Independent Director
- 57.85K
- Albert D. Dyrness
- Independent Director
- 59.35K
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call